HCP 04
Medical Oncologist · Germany
“Progression on the class tells me the mechanism is exhausted — I switch rather than persist.”
Strategic intelligence
Explore whether the congress evidence helps answer a broader strategic intelligence question that reaches beyond the predefined KBQ framework.
KBQ — a congress-specific analytical question defined before the congress.
KIQ — a broader strategic intelligence question that congress evidence may help to inform.
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Evidence availability
Relevant evidence found in 9 of 16 HCP conversations.
The congress evidence suggests HCP thinking about post-CDK4/6 sequencing is actively evolving rather than settled. A change of mechanism after progression is now the dominant instinct, but decisions are increasingly framed as individualised and informed by molecular findings and the interval to recurrence.
HCP 04
Medical Oncologist · Germany
“Progression on the class tells me the mechanism is exhausted — I switch rather than persist.”
HCP 09
Medical Oncologist · United States
“Increasingly I am letting the molecular findings and ctDNA dynamics guide what I choose next.”
HCP 13
Medical Oncologist · United States
“In selected late recurrences I would still consider continuing the class with modification.”
The available evidence could also help explore these. Select one to rerun the analysis.